ev3 Inc

ev3 — Q3 2009 Earnings Presentation

17 slides from ev3's earnings presentation, Oct 27, 2009

  1. Slide 1: Q3 '09 Highlights

    Q3 '09 Highlights October 27, 2009

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "intend,

  3. Slide 3: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation. ev3 uses non-GAAP financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. How

  4. Slide 4: Q3 '09 Financial Summary

    Q3 '09 Financial Summary Net product sales of $112.8 million +13% vs. Q3 2008; +15% constant currency* Peripheral vascular sales, excluding atherectomy*, +5% vs. Q3 2008; +6% constant currency* Peripheral stents +8% vs. Q3 2008; +10% constant currency* Atherectomy -7% vs. Q3 2008 Neurovascular sales

  5. Slide 5: Q3 '09 Operational Highlights - Peripheral Vascular

    Q3 '09 Operational Highlights - - Peripheral Vascular TurboHawk Plaque Excision System launched in U.S. for surgical use Incremental opportunity to treat moderate to severely calcified above-the-knee lesions New 'Super Cutter' blade, jog and drive shaft combine to remove more plaque per pass Designe

  6. Slide 6: Q3 '09 Operational Highlights - Neurovascular

    Q3 '09 Operational Highlights - - Neurovascular Chestnut Medical products launched Pipeline Embolization Device (PED) launched in Europe and other International markets Alligator Retrieval Device (ARD) launched worldwide Initiated physician preference testing for AXIUM PGLA & Nylon coils in U.S. and

  7. Slide 7: Actual Results vs. Last Quarter & Year Ago

    Actual Results vs. Last Quarter & Year Ago * Constant Currency; For reconciliations, see our website at www.ev3.net. ** All quarters presented are adjusted for amortization and non-cash stock-based compensation. Q2 2009 is also adjusted for a non-cash tax benefit resulting from the acquisition of Ch

  8. Slide 8: Total Q3 '09 Product Revenue Growth of 15%*

    Total Q3 '09 Product Revenue Growth of 15%* Q4 Q1 Q2 Q3 Q3 East 105.6 100.4 109.1 100 112.8 Q4 Q1 Q2 Q3 Q3 East 39.4 38.7 41.4 36.6 44.4 Total International ($M) +26%* Q4 Q1 Q2 Q3 Q3 East 68.1 66.2 72 66.9 67.6 Worldwide Peripheral Vascular ($M) +2%* Q4 Q1 Q2 Q3 Q3 East 37.5 34.2 37.1 33.1 45.2 Worl

  9. Slide 9: Balance Sheet is Strengthening - We are Generating Cash

    Balance Sheet is Strengthening - - We are Generating Cash Cash / Cash Equivalents Cash flow from operating activities totaled $20.9M in Q3 '09 Cash/cash equivalents increased $20.1M Q3 '09 vs Q2 '09 Inventory days increased 3% in Q3 '09 vs Q3 '08 Total debt decreased to $7.1M Q3 08 Q4 08 Q1 09 Q2 09

  10. Slide 10: Improving Cost Structure - Continuing Progress

    Improving Cost Structure - Continuing Progress Q3 08 Q3 09 East 0.642 0.746 Gross Margin % of sales SG&A % of sales Q3 08 Q3 09 East 0.5 0.49 Favorable product mix, improved yields and labor efficiency, higher volumes Continued focus on leveraging cost structure and improving margins

  11. Slide 11: Annualized Net Sales Per Territory

    Annualized Net Sales Per Territory Q3'09 up 29% vs. Q3'08 Key Drivers Atherectomy Clinical Specialists Corporate Account penetration Referral Market development DEFINITIVE clinical data Neuro business already > $2M per territory Increasing Peripheral Vascular Sales Force Productivity in U.S. Q3 08 Q

  12. Slide 12: Financial Summary: Continuing to Improve Performance

    Financial Summary: Continuing to Improve Performance Net Product Sales* $100,018 $105,656 $100,395 $109,086 $112,838 Gross Profit $68,747 $71,316 $69,407 $78,608 $84,230 Gross Margin 64.2% 67.2% 69.1% 72.1% 74.6% Net Income (loss) $(7,310) $(291,120) $(1,809) $23,989 $6,736 Adjusted EPS per diluted

  13. Slide 13: Guidance - As of October 27, 2009

    Guidance - As of October 27, 2009 Full-Year 2009 Guidance Revenues: Q4 2009: $124 to $128 million Full-Year 2009: $446 to $450 million Adjusted EPS1 per diluted share: Q4 2009: $0.20 to $0.241,2 Full-Year 2009: $0.58 to $0.621,2 Adjusted EPS guidance is based on weighted average diluted shares outst

  14. Slide 14: Business Model Structure - Select P&L Information

    2008 % of sales 2007 2009 Goal Business Model Structure - - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 72% Selling, general & administrative* 55% 69% 50% Taxes** 0.4% 0.3% 1% Research & development 12% 17% 11% Stock-based comp, amortization & contingent consideration 11% 11% 10

  15. Slide 15: Continue to Stay Focused on Profitable Growth

    Continue to Stay Focused on Profitable Growth Long-term profitable revenue growth Improve cost structure Increase sales force productivity Grow international sales Clinical evidence New products 1 2 3 4 5

  16. Slide 16: In Summary: Why Invest in ev3

    In Summary: Why Invest in ev3 Peripheral vascular and Neurovascular procedures less vulnerable to macro-economic environment broadest product offering in $2B growing global market Generating cash and clear roadmap for sustained, profitable growth increasing productivity, clinical evidence, new produ

  17. Slide 17: Contact Info

    NASDAQ: EVVV www.ev3.net Contact Info: Julie Tracy - Sr. VP, Chief Communications Officer (949) 680-1375 jtracy@ev3.net

ev3 — Q3 2009 Earnings Presentation on 6ix